Heron Therapeutics (NASDAQ:HRTX) Now Covered by Capital One Financial

Equities researchers at Capital One Financial began coverage on shares of Heron Therapeutics (NASDAQ:HRTX) in a research report issued to clients and investors on Tuesday, Marketbeat reports. The brokerage set an “overweight” rating and a $6.00 price target on the biotechnology company’s stock. Capital One Financial‘s price objective would suggest a potential upside of 126.42% from the company’s current price.

A number of other equities analysts also recently issued reports on HRTX. Needham & Company LLC reissued a “buy” rating and issued a $5.00 price objective on shares of Heron Therapeutics in a report on Thursday, April 11th. StockNews.com raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th.

Heron Therapeutics Stock Performance

NASDAQ:HRTX opened at $2.65 on Tuesday. The firm has a 50-day simple moving average of $2.75 and a two-hundred day simple moving average of $1.96. Heron Therapeutics has a fifty-two week low of $0.50 and a fifty-two week high of $3.22. The firm has a market cap of $398.37 million, a P/E ratio of -3.08 and a beta of 1.68.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.08. The company had revenue of $34.23 million during the quarter, compared to the consensus estimate of $30.98 million. On average, equities research analysts predict that Heron Therapeutics will post -0.22 EPS for the current year.

Institutional Investors Weigh In On Heron Therapeutics

Large investors have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. increased its position in Heron Therapeutics by 100.0% during the third quarter. Adage Capital Partners GP L.L.C. now owns 2,000,000 shares of the biotechnology company’s stock valued at $2,060,000 after acquiring an additional 1,000,000 shares during the last quarter. JW Asset Management LLC increased its position in Heron Therapeutics by 9.1% during the third quarter. JW Asset Management LLC now owns 2,407,418 shares of the biotechnology company’s stock valued at $2,480,000 after acquiring an additional 200,000 shares during the last quarter. Congress Park Capital LLC increased its position in Heron Therapeutics by 205.3% during the fourth quarter. Congress Park Capital LLC now owns 1,798,650 shares of the biotechnology company’s stock valued at $3,058,000 after acquiring an additional 1,209,500 shares during the last quarter. SG Americas Securities LLC bought a new position in Heron Therapeutics during the third quarter valued at $31,000. Finally, Tejara Capital Ltd increased its position in Heron Therapeutics by 28.6% during the third quarter. Tejara Capital Ltd now owns 2,109,681 shares of the biotechnology company’s stock valued at $2,173,000 after acquiring an additional 469,548 shares during the last quarter. Institutional investors own 80.01% of the company’s stock.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.